Encequidar mesylate

• CAS: 849675-87-2
• Catalog Number: ACM849675872
• Category: Inhibitors
• Molecular Weight: 784.84
• Molecular Formula: C39H40N6O10S
• Description: Encequidar, also known as HM-30181, is an oral P-glycoprotein (P-gp) inhibitor developed to enhance the oral bioavailability of P-gp substrate drugs. Encequidar showed the highest potency (IC(50)=0.63nM) among several MDR1 inhibitors, including cycloporin A, XR9576, and GF120918, and effectively blocked transepithelial transport of paclitaxel in MDCK monolayers (IC(50)=35.4nM). Encequidar is currently under clinical trials.
• Synonyms: HM30181; HM-30181; HM 30181; HM-30181 mesylate; Encequidar mesylate
• IUPAC Name: N-(2-(2-(4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl)-4-oxo-4H-chromene-2-carboxamide methanesulfonate
• Canonical SMILES: O=C(NC1=CC(OC)=C(C=C1C2=NN(N=N2)C3=CC=C(C=C3)CCN4CC5=C(CC4)C=C(C(OC)=C5)OC)OC)C6=CC(C7=C(C=CC=C7)O6)=O.OS(=O)(C)=O
• InChI: InChI=1S/C38H36N6O7.CH4O3S/c1-47-32-17-24-14-16-43(22-25(24)18-33(32)48-2)15-13-23-9-11-26(12-10-23)44-41-37(40-42-44)28-19-34(49-3)35(50-4)20-29(28)39-38(46)36-21-30(45)27-7-5-6-8-31(27)51-36;1-5(2,3)4/h5-12,17-21H,13-16,22H2,1-4H3,(H,39,46);1H3,(H,2,3,4)
• InChI Key: PEKXWELLWNPUOK-UHFFFAOYSA-N
• Solubility: Soluble in DMSO, not in water
• Appearance: White solid powder
• Shelf Life: >2 years if stored properly
• Storage: Dry, dark and at 0-4 °C for short term (days to weeks) or -20 °C for long term (months to years).
• Alternative CAS: 849675-66-7 (free base); 849675-87-2 (mesylate); 849675-88-3 (HCl)
• Biological Target: Encequidar mesylate (HM30181 mesylate; HM30181A mesylate) is a competitive and potent P-glycoprotein inhibitor.
• Drug Formulation: This drug may be formulated in DMSO
• Elemental Analysis: C, 59.68; H, 5.14; N, 10.71; O, 20.39; S, 4.08
• Exact Mass: 784.2527
• HS Tariff Code: 2934.99.9001
• In Vitro Activity: Based on these data, the IC50 of encequidar for inhibition of P-gp in Caco-2 intestinal cells was determined to be 53 nM,; demonstrating that encequidar potently inhibits P-gp and prevents the efflux of paclitaxel from intestinal cells in vitro.; Reference: J Med Chem. 2021 Apr 8;64(7):3677-3693. https://pubmed.ncbi.nlm.nih.gov/33729781/
• In Vivo Activity: 40 mg/kg paclitaxel (in combination with 20 mg/kg encequidar) suppressed tumor growth by 94% and induced remission of tumor; growth until day 47, an outcome superior to the IV paclitaxel arm included in the study. The results of this study demonstrate the; ability of encequidar to inhibit P-gp and facilitate the absorption of paclitaxel to therapeutically effective plasma concentrations in; vivo. Clinically, paclitaxel is used to treat many different types of cancers, including breast, lung, and ovarian cancer.; Reference: J Med Chem. 2021 Apr 8;64(7):3677-3693. https://pubmed.ncbi.nlm.nih.gov/33729781/
• Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
• Stock Solution Storage: 0-4 °C for short term (days to weeks), or -20 °C for long term (months).